Philippe Gevaert

TL;DR: The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012 and addresses areas not extensively covered in EPOS2012 such as paediatric CRS and sinus surgery.

TL;DR: The European Position Paper on Rhinosinusitis and Nasal Polyps 2012 as discussed by the authors is the update of similar evidence-based position papers published in 2005 and 2007, it contains chapters on definitions and classification, we now also proposed definitions for difficult to treat rhinositis, control of disease, and better definitions for rhinosinitis in children.

TL;DR: Wang et al. as mentioned in this paper suggested that CRS, NP, and CF-NP are distinct disease entities within the group of chronic sinus diseases, based on cellular and mediator profiles.

TL;DR: It is suggested that there is an association between increased levels of total IgE, specific Ig E, and eosinophilic inflammation in NPs, which may be of relevance in the pathophysiology of nasal polyposis.

TL;DR: Among adults with symptomatic chronic sinusitis and nasal polyposis refractory to intranasal corticosteroids, the addition of subcutaneous dupilumab to mometasone furoate nasal spray compared with mometAsone alone reduced endoscopic nasal polyp burden after 16 weeks.